Compare CAC & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | FLGT |
|---|---|---|
| Founded | 1875 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 697.3M |
| IPO Year | 1997 | 2016 |
| Metric | CAC | FLGT |
|---|---|---|
| Price | $45.52 | $26.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $47.33 | $28.33 |
| AVG Volume (30 Days) | 72.7K | ★ 272.3K |
| Earning Date | 01-27-2026 | 11-07-2025 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | $215,172,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $44.50 | $16.84 |
| Revenue Next Year | $7.03 | $9.74 |
| P/E Ratio | $12.94 | ★ N/A |
| Revenue Growth | ★ 27.50 | 13.61 |
| 52 Week Low | $34.53 | $14.57 |
| 52 Week High | $46.99 | $31.04 |
| Indicator | CAC | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 77.21 | 45.25 |
| Support Level | $41.38 | $26.69 |
| Resistance Level | $41.60 | $31.04 |
| Average True Range (ATR) | 1.24 | 0.74 |
| MACD | 0.39 | -0.45 |
| Stochastic Oscillator | 95.25 | 7.59 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.